No Data
No Data
No Data
Express News | Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 Following Positive Safety Review Committee (Src) Recommendation for Pas-004 in Ongoing Phase 1 Clinical Trial
Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting
10-Q: Quarterly report
Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting
Express News | Pasithea Therapeutics Announces the First Cohort Has Completed the Initial Dosing in Its Phase 1 Trial Evaluating Pas-004 in Ras, Nf1 and Raf Mutated Cancers
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for Its Phase 1 Trial of PAS-004
No Data